Last reviewed · How we verify
NCT07295509
A Study of Picankibart in Patients With Active Psoriatic Arthritis
Phase 2, PHASE3 trial testing Placebo in Psoriatic Arthritis in 222 participants. Currently enrolling.
31 December 2029
Quick facts
| Lead sponsor | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. |
|---|---|
| Phase | Phase 2, PHASE3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 222 |
| Start date | 18 December 2025 |
| Primary completion | 31 December 2029 |
| Estimated completion | 31 December 2029 |
| Sites | 1 location across China |
Drugs / interventions tested
- Placebo
- Picankibart — full drug profile →
Conditions studied
- Psoriatic Arthritis — all drugs for Psoriatic Arthritis →
Sponsor
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. — full company profile →
Who can join
Adults 18 to 75, any sex, with Psoriatic Arthritis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a multicenter, randomized, double-blind, placebo-controlled Phase II/III clinical trial evaluating the efficacy and safety of picankibart (IBI112) in patients with active psoriatic arthritis (PsA). The study consists of two stages: Phase II dose-finding (n=90) and Phase III confirmatory (n=132). Participants will receive subcutaneous (SC) injections of either picankibart (200mg) or placebo with different dosing schedules, with placebo crossover to active treatment at Week 26. The Phase II portion will identify optimal dosing for Phase III, which will confirm efficacy. The study will evaluate improvements in joint symptoms, physical function, quality of life, and skin manifestations. Primary endpoint is percentage of participants who achieved an American College of Rheumatology (ACR) 20 Response at Week 24.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07295509
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Picankibart
Trials testing the same drug.
- NCT06945107 — A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin · Phase 3 · active not recruiting
Other recruiting trials for Psoriatic Arthritis
Currently open trials in the same condition.
- NCT07286058 — Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis · Phase 3 · recruiting
- NCT07290036 — A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adu · Phase 1 · recruiting
- NCT07180537 — Creating Health Course Study for People With Rheumatological Conditions · NA · recruiting
- NCT06888193 — A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® · Phase 1 · recruiting
- NCT07148414 — A Study of SPY072 in Rheumatic Disease · Phase 2 · recruiting
Other Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. trials
Trials by the same sponsor.
- NCT07490262 — A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular · Phase 2, PHASE3 · recruiting
- NCT07377643 — IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer · Phase 3 · recruiting
- NCT07265284 — A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis · Phase 3 · recruiting
- NCT06945107 — A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin · Phase 3 · active not recruiting
- NCT06963281 — Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07295509 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
- Last refreshed: 20 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07295509.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing